We are a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. We are developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections including those caused by methicillin-resistantstaphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, we are discovering antibiotics for infections caused by Gram-negative bacteria using our structure based discovery platform. In December 2011, we reported top line data from our first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI. All primary and secondary endpoints for the ESTABLISH 1 study were achieved. In December 2012, we completed enrollment in our second Phase 3 clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI. We expect to report top line data from this second Phase 3 clinical trial near the end of the first quarter in 2013. We currently expect to submit a New Drug Application, or NDA, to the Food and Drug Administration, or FDA, for tedizolid phosphate for the treatment of ABSSSI during the second half of 2013.
![Trius Therapeutics logo](https://files.capedge.com/424B5/0001193125-12-418573/g421787g45h63.jpg)
Company profile
Ticker
TSRX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RX3 Pharmaceuticals Inc
SEC CIK
Corporate docs
IRS number
201320630
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
10 Oct 13
15-12B
Securities registration termination
23 Sep 13
EFFECT
Notice of effectiveness
16 Sep 13
EFFECT
Notice of effectiveness
16 Sep 13
POS AM
Prospectus update (post-effective amendment)
13 Sep 13
POS AM
Prospectus update (post-effective amendment)
13 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Sep 13
Latest ownership filings
SC 13G/A
Trius Therapeutics Inc
14 Feb 14
SC 13D/A
Trius Therapeutics Inc
13 Sep 13
SC 13D/A
Trius Therapeutics Inc
26 Aug 13
SC 13D
Trius Therapeutics Inc
9 Aug 13
SC 13D/A
SOFINNOVA VENTURE PARTNERS VII L P
13 Jan 12
SC 13D/A
SOFINNOVA VENTURE PARTNERS VII L P
6 Dec 11
SC 13D
InterWest Partners IX, LP
16 Aug 10
SC 13D
SOFINNOVA VENTURE PARTNERS VII L P
16 Aug 10
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|